DE69434934D1 - Verfahren zur induzierung und zur erhaltung neuronalen zellen - Google Patents
Verfahren zur induzierung und zur erhaltung neuronalen zellenInfo
- Publication number
- DE69434934D1 DE69434934D1 DE69434934T DE69434934T DE69434934D1 DE 69434934 D1 DE69434934 D1 DE 69434934D1 DE 69434934 T DE69434934 T DE 69434934T DE 69434934 T DE69434934 T DE 69434934T DE 69434934 D1 DE69434934 D1 DE 69434934D1
- Authority
- DE
- Germany
- Prior art keywords
- inducing
- neuronal
- neuronal cells
- conserving
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13674893A | 1993-10-14 | 1993-10-14 | |
PCT/US1994/011745 WO1995010611A1 (en) | 1993-10-14 | 1994-10-14 | Method of inducing and maintaining neuronal cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69434934D1 true DE69434934D1 (de) | 2007-04-12 |
Family
ID=22474198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434934T Expired - Lifetime DE69434934D1 (de) | 1993-10-14 | 1994-10-14 | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080261879A1 (de) |
EP (1) | EP0726948B1 (de) |
JP (1) | JPH09503673A (de) |
AT (1) | ATE355369T1 (de) |
AU (1) | AU701623B2 (de) |
CA (1) | CA2174098C (de) |
DE (1) | DE69434934D1 (de) |
WO (1) | WO1995010611A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US6506729B1 (en) | 1991-03-11 | 2003-01-14 | Curis, Inc. | Methods and compositions for the treatment and prevention of Parkinson's disease |
US6723698B2 (en) | 1991-03-11 | 2004-04-20 | Curis, Inc. | Methods and compositions for the treatment of motor neuron injury and neuropathy |
ATE244574T1 (de) | 1996-03-22 | 2003-07-15 | Curis Inc | Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
AU2003231603B2 (en) * | 1998-03-09 | 2006-08-24 | Genetics Institute, Llc | Use of follistatin to modulate GDF-8 and BMP-11 |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
EP0950414A1 (de) * | 1998-04-08 | 1999-10-20 | Boehringer Mannheim Gmbh | Verwendung einer Kombination eines knocheninduzierenden Proteins und eines dorsalizing Faktors zur Knorpelinduktion |
EP0950415A1 (de) * | 1998-04-08 | 1999-10-20 | Roche Diagnostics GmbH | Verwendung einer Kombination eines knocheninduzierenden Proteins und eines dorsalisierenden Faktors zur Knorpelinduktion |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
EP1109579B1 (de) * | 1998-09-03 | 2005-12-07 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG UND ZUM VERTRIEB VON PHARMAKA mbh | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
AU1040600A (en) * | 1999-03-16 | 2000-10-04 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of tgf-beta inhibitors for treating cerebral disorders |
JP4795616B2 (ja) | 2000-06-20 | 2011-10-19 | イーエス・セル・インターナショナル・プライヴェート・リミテッド | Bmp−2経路アンタゴニストの存在下においてes細胞を培養することによって胚性幹細胞の分化をコントロールする方法 |
GB0207829D0 (en) * | 2002-04-04 | 2002-05-15 | Isis Innovations Ltd | Stimulation of nerve cell regeneration |
RU2006122519A (ru) * | 2003-12-24 | 2008-01-27 | Сайос, Инк. (Us) | Лечение злокачественных глиом ингибиторами тфр-бэта |
EP2332977B1 (de) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | AvtRII-Rezeptor-Polypeptide |
KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
EP2446896A1 (de) | 2006-12-18 | 2012-05-02 | Acceleron Pharma, Inc. | Activin-AcrtRII-Antagonisten zur Verwendung zur Erhöhung der Erythrozytenspiegel, zur Erhöhung der Reticulozytenspiegel oder zur Förderung der Erythropoiesis |
RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EA025371B1 (ru) | 2007-02-09 | 2016-12-30 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
EP3243524A1 (de) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonisten und verfahren zur verringerung oder inhibierung der fsh-sekretion |
EP3363453A1 (de) | 2008-06-26 | 2018-08-22 | Acceleron Pharma Inc. | Löslicher actriia als activin-actriia-antagonist zur verwendung in der behandlung von anämie oder knochenkrankheiten |
LT3494986T (lt) | 2008-08-14 | 2020-07-10 | Acceleron Pharma Inc. | Gdf gaudyklės |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
KR20190090049A (ko) | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
US20120121576A1 (en) | 2010-11-08 | 2012-05-17 | Jasbir Seehra | Actriia binding agents and uses thereof |
CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
WO2014201133A1 (en) * | 2013-06-11 | 2014-12-18 | President And Fellows Of Harvard College | Compositions and methods for improving induced neuron generation |
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
KR20210119546A (ko) | 2014-06-04 | 2021-10-05 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
KR20170129233A (ko) | 2015-03-26 | 2017-11-24 | 악셀레론 파마 인코포레이티드 | 폴리스타틴-관련된 융합 단백질 및 이들의 용도 |
CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
HRP20230706T1 (hr) | 2017-05-04 | 2023-10-13 | Acceleron Pharma Inc. | Fuzijski proteini tgf-beta receptora tipa ii i njihove upotrebe |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
US5182375A (en) * | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
AU623922B2 (en) * | 1988-08-04 | 1992-05-28 | Amrad Operations Pty. Limited | In vitro propagation of embryonic stem cells |
-
1994
- 1994-10-14 DE DE69434934T patent/DE69434934D1/de not_active Expired - Lifetime
- 1994-10-14 AU AU79806/94A patent/AU701623B2/en not_active Expired
- 1994-10-14 AT AT94930791T patent/ATE355369T1/de not_active IP Right Cessation
- 1994-10-14 CA CA2174098A patent/CA2174098C/en not_active Expired - Lifetime
- 1994-10-14 JP JP7512112A patent/JPH09503673A/ja active Pending
- 1994-10-14 EP EP94930791A patent/EP0726948B1/de not_active Expired - Lifetime
- 1994-10-14 WO PCT/US1994/011745 patent/WO1995010611A1/en active IP Right Grant
-
2007
- 2007-10-31 US US11/981,846 patent/US20080261879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2174098A1 (en) | 1995-04-20 |
EP0726948B1 (de) | 2007-02-28 |
AU7980694A (en) | 1995-05-04 |
ATE355369T1 (de) | 2006-03-15 |
EP0726948A1 (de) | 1996-08-21 |
US20080261879A1 (en) | 2008-10-23 |
CA2174098C (en) | 2011-01-25 |
JPH09503673A (ja) | 1997-04-15 |
AU701623C (en) | 1995-05-04 |
WO1995010611A1 (en) | 1995-04-20 |
AU701623B2 (en) | 1999-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434934D1 (de) | Verfahren zur induzierung und zur erhaltung neuronalen zellen | |
DE59813404D1 (de) | Neurale vorläuferzellen, verfahren zu ihrer herstellung und ihre verwendung zur therapie von neuralen defekten | |
ATE241353T1 (de) | Fumarsäurederivate zur behandlung der transplantatabstossung | |
IL192762A0 (en) | Method for identifying cell differentiation factors | |
CA2444724A1 (en) | Method for differentiating mesenchymal stem cells into neural cells | |
ATE180674T1 (de) | Osteoblastswachstumfordernde zusammensetzungen die pdgf und vitamin-d enthalten | |
WO2003024472A3 (en) | Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof | |
DE3878951T2 (de) | Verwendung von milch-glycoproteinen zur mundhygiene. | |
DE69627467T2 (de) | Verwendung von zusammensetzungen mit benzoylperoxyd, glycolsäure und zink zur behandlung von dermatologischen krankheiten | |
ATE443758T1 (de) | Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen | |
ATE91628T1 (de) | Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten. | |
DE69025922D1 (de) | Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen | |
ATE330608T1 (de) | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen | |
DE60216281D1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
DE69021415T2 (de) | Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen. | |
ATE303818T1 (de) | Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen | |
DE69321885D1 (de) | Verfahren zur fermentativen Herstellung von 10-Hydroxy-C18-Carbonsäure und Gamma-Dodekalaktonderivaten | |
WO2003000852A3 (en) | Method of producing region-specific neurons from human neuronal stem cells | |
NO890801L (no) | Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer. | |
DE69929189D1 (de) | Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche | |
TW232014B (de) | ||
Selye et al. | Acceleration and inhibition of wound healing by topical treatment with different types of inflammatory irritants | |
ES2180433A1 (es) | Empleo de celulas madre hematopoyeticas en la generacion de celulas madre neurales. | |
Tanaka et al. | Flower-inducing activity of lysine in Lemna paucicostata 151 cultured on nitrogen-deficient medium | |
WO2000022097A3 (en) | Periferal blood mensenchymal precursor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |